
Sign up to save your podcasts
Or


Discussion of the RE-LY trial subgroup for the secondary prevention of stroke, and phase 2 results of gene therapy for Parkinson's disease.
By The Lancet NeurologyDiscussion of the RE-LY trial subgroup for the secondary prevention of stroke, and phase 2 results of gene therapy for Parkinson's disease.

43,589 Listeners

292 Listeners

518 Listeners

50 Listeners

112,200 Listeners

93 Listeners

513 Listeners

189 Listeners

61 Listeners

82 Listeners

0 Listeners